Massachusetts H2212 mandates discussions on opioid risks before issuing initial and third prescriptions.
Massachusetts H2212 requires healthcare practitioners to discuss opioid risks with patients before issuing the initial and third prescriptions for Schedule II controlled substances or opioid pain relievers. This includes discussing addiction risks, reasons for the prescription, alternative treatments, and the dangers of combining opioids with alcohol or other depressants. This requirement does not apply to patients in active cancer treatment, hospice care, or long-term care facilities, or those prescribed opioids for substance abuse treatment.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.